Diverse leadership provides more opportunity for innovation and higher performance in financial return, says diversity and inclusion chair and biotech executive.
Biogen will halt all clinical trial activity on its Alzheimer’s drug, aducanumab, after its failure in Phase III trials, according to its first quarter financials.
AbbVie receives approval from the US FDA for its newest psoriasis drug, Skyrizi, which looks set to recoup some of Humira’s revenue when it loses patent protection.
CPhI North America donates $10,000 to iBIO’s Educate Center to help fund STEM programs for girls and solidifies its partnership with the association to support Illinois as a growing life sciences hub.
The expanding cell therapy market has placed new demands on supply chain services, with their shipment requirements and competition in the logistics industry rising.
Fuji Pharma signs agreement to receive an exclusive supply of the ustekinumab biosimilar for the Japanese market, furthering a previous investment agreement.
The industry focuses investments where there is the highest potential returns, but one panel at BIO-Europe Spring suggested multiple partners could boost outcomes in underserved therapeutic areas.
Bringing together the food industry’s know-how and pharma’s manufacturing expertise, the new joint venture from Lonza and Chr. Hansen is positioned to pioneer the live biotherapeutic products space – addressing medical needs not met with ‘conventional’...
Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.
Pall Biotech signs an industry participation agreement with the New Jersey Innovation Institute to create two centres designed to develop and manufacture cell and gene therapies.
Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimer’s – a key part of the former’s pipeline.
Abzena and Lipum enter agreement for the development of biologics for juvenile idiopathic arthritis, using the former’s proprietary cell line and GMP resources.
In a step towards the commercialisation of its ‘off-the-shelf’ CAR-T therapies, Cellectis begins construction of a facility in France and enters lease agreement for US facility.
Regenerative medicine raised $13.3bn in funds during 2018 but investors question whether treatments can be manufactured consistently, according to AMR annual report.
MaxCyte announces a partnership with Kite to explore the use of flow electroporation technology to enable the non-viral cell engineering of CAR-T drug candidates.
Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.
ABL will use WuXi’s platforms in an extended agreement for the development and commercialization of its bispecific antibodies, using the recently launched WuXiBody platform.
Celltrion Healthcare’s head of medical and marketing outlines how the US biosimilar market is evolving and how manufacturing efficiency could become a key distinguisher from competitors.
In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.
The US market for insulin biosimilars is set to open up in 2020, and the head of biopharmaceuticals at Sandoz explained why he is confident of an ‘acceleration’ of the US biosimilar market in the coming years.
ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.
